• Citer

An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case.

par Ades, F;Senterre, Christelle ;Zardavas, Dimitros ;de Azambuja, Evandro ;Popescu, Razvan;Parent, Florence ;Piccart-Gebhart, Martine
Référence European journal of cancer, 50, 18, page (3089-3097)
Publication Publié, 2014-12

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case.
Auteur:	Ades, F; Senterre, Christelle; Zardavas, Dimitros; de Azambuja, Evandro; Popescu, Razvan; Parent, Florence; Piccart-Gebhart, Martine
Informations sur la publication:	European journal of cancer, 50, 18, page (3089-3097)
Statut de publication:	Publié, 2014-12
Sujet CREF:	Cancérologie
	Santé publique
Mots-clés:	Breast cancer
	Drug reimbursement
	European Union
	Health expenditure
	Health policy
	Trastuzumab
MeSH keywords:	Antibodies, Monoclonal, Humanized -- economics -- therapeutic use
	Antineoplastic Agents -- economics -- therapeutic use
	Breast Neoplasms -- drug therapy -- economics
	Chemotherapy, Adjuvant -- economics
	Cost-Benefit Analysis
	Drug Approval -- economics
	European Union -- economics
	Female
	Health Expenditures -- statistics & numerical data
	Health Policy -- economics
	Humans
	Neoplasm Metastasis
	Reimbursement Mechanisms
	Time Factors
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0959-8049
	info:doi/10.1016/j.ejca.2014.09.011
	info:pii/S0959-8049(14)00961-7
	info:scp/84925225626
	info:pmid/25446375